Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) The use of a compound of Formula I,



(I)

wherein

Q is

1) H,

2) aryl,

3) heteroaryl or

4) a group of formula



;

wherein aryl and heteroaryl is unsubstituted or substituted with 1 to 4 substituents selected from R^a;

A is

1) H,

2) $(C_1\text{-}C_6)$alkyl or

3) $(C_3\text{-}C_5)$cycloalkyl;

B is independently selected from

1) H,

2) halogen or

3) $(C_1\text{-}C_6)$alkyl;

or symbols B together may form a double or triple bond between the atoms to which they are attached;

D is aryl or heteroaryl, which may be unsubstituted or substituted with one to four groups selected from R^d;

R1 is

1) H,

2) $(C_1\text{-}C_6)$alkyl or

3) $(C_3\text{-}C_7)$cycloalkyl;

R2 is independently selected from

1) H,

2) $(C_1\text{-}C_6)$alkyl,

3) $(C_2\text{-}C_6)$alkenyl,

4) $(C_2\text{-}C_6)$alkynyl,

5) $(C_3\text{-}C_7)$cycloalkyl,

6) $(C_3\text{-}C_7)$cycloalkyl$(C_1\text{-}C_6)$alkyl,

7) $-NH_2$ or

8) $-C(=NR^b)NR^bR^b$;

wherein symbols R^b together with the atoms to which they are attached may also form a 5 to 6 membered unsaturated or saturated ring; or R2 and R2 together with the nitrogen to which

they are attached may form a 5 to 7 membered ring containing 1 to 3 heteroatoms selected from N, O and S, wherein the formed ring may be saturated or unsaturated;

R3 is

1) H,

2) $(C_1\text{-}C_6)$alkyl,

3) $(C_2\text{-}C_6)$alkenyl,

4) $(C_2\text{-}C_6)$alkynyl or

5) $(C_3\text{-}C_7)$cycloalkyl;

R4 is

1) H,

2) $(C_1\text{-}C_6)$alkyl,

3) $(C_2\text{-}C_6)$alkenyl,

4) $(C_2\text{-}C_6)$alkynyl,

5) Cy,

6) Cy-$(C_1\text{-}C_6)$alkyl,

7) Cy-$(C_2\text{-}C_6)$alkenyl or

8) Cy-$(C_2\text{-}C_6)$alkynyl;

wherein alkyl, alkenyl, alkynyl and Cy are each optionally substituted with one to two substituents selected from R^d;

R5 is

1) H,

2) $(C_1\text{-}C_6)$alkyl,

3) $(C_2\text{-}C_6)$alkenyl,

4) $(C_2\text{-}C_6)$alkynyl,

5) aryl,

6) aryl-(C_1-C_6)alkyl,

7) heteroaryl,

8) heteroaryl(C_1-C_6)alkyl or

9) $-(CH_2)_kC(O)NHR^b$;

wherein aryl and heteroaryl are each optionally substituted with one to two substituents selected from R^d; or

R4 and R5 together with the atom to which they are attached form a 3 to 7 membered ring containing 0 to 2 heteroatoms selected from N, O and S, wherein the said ring can be substituted with one to three substituents selected from R^d; or the said ring can be fused to aryl or heteroaryl which may be substituted with one to three substituents selected from R^d;

R^a is independently

1) H,

2) Halogen,

3) $-OR^b$,

4) (C_1-C_6)alkyl or

5) $-CF_3$;

R^b is independently

1) hydrogen,

2) (C_1-C_6)alkyl,

3) (C_2-C_6)alkenyl,

4) (C_2-C_6)alkynyl,

5) Cy or

6) Cy-(C_1-C_4)alkyl;

R^d is independently

1) a group selected from R^c,

2) $(C_1\text{-}C_6)$alkyl,

3) $(C_2\text{-}C_6)$alkenyl,

4) $(C_2\text{-}C_6)$alkynyl,

5) aryl,

6) aryl-$(C_1\text{-}C_6)$alkyl,

7) heteroaryl-$(C_1\text{-}C_6)$alkyl,

8) $(C_3\text{-}C_7)$cycloalkyl or

9) heterocyclyl;

wherein alkyl, alkenyl, alkynyl, aryl and heteroaryl are each optionally substituted with one to four substituents independently selected from R^c;

R^c is independently

1) a group selected from R^a,

2) $-NO_2$,

3) $-SR^b$,

4) $-NR^bR^b$,

5) $-CN$ or

6) $-NR^bC(O)R^b$;

k is an integer 0 or 1;

n is an integer from 0 to 3; and

Cy is cycloalkyl, heterocyclyl, aryl or heteroaryl;

or of a pharmaceutically acceptable salt or ester thereof, for the preparation of a medicament for treating a disease or condition in mammals where an interaction with somatostatin receptor subtypes 1 and/or 4 is indicated to be useful.

2. (Original) The use according to claim 1, where the compound is an agonist.

3. (Original) The use according to claim 1, where the compound is an antagonist.

4. (Original) The use according to claim 1, where the compound is SSTR1 selective.

5. (Original) The use according to claim 1, where the compound is SSTR4 selective.

6. (Currently Amended) The use according to claim 1, wherein the compound of Formula I is a compound of Formula IA



(IA)

or pharmaceutically acceptable salt or ester thereof,

wherein R2, R3, B and D are as defined in claim 1; R4 is benzyl which can be optionally substituted with one to two substituents selected from R^a ~~as defined in claim 1~~; and

n is an integer 1 or 2.

7. (Currently Amended) The use according to claim 1, wherein the compound of Formula I is a compound of Formula IB



(IB)

or pharmaceutically acceptable salt or ester thereof,

~~wherein R2, R3, B and D are as defined in claim 1;~~

R4 is phenyl or benzyl, which is unsubstituted or substituted with 1 to 2 substituents selected from R^a ~~as defined in claim 1~~;

R5 is hydrogen or $(C_1\text{-}C_6)$alkyl; and

n is an integer 1 or 2.

8. (Currently Amended) The use according to claim 1, wherein the compound of Formula I is a compound of Formula IC



(IC)

or pharmaceutically acceptable salt or ester thereof,

~~wherein R3, Q and D are as defined in claim 1;~~

R2 is independently selected from

1) H,

2) $(C_1\text{-}C_3)$alkyl,

3) $(C_1\text{-}C_3)$cycloalkyl or

4) –C(=NH)NH2; and

n is an integer 1 or 2.

9. (Currently Amended) The use according to claim 1, wherein the compound of Formula I is a compound of Formula ID



(ID)

or pharmaceutically acceptable salt or ester thereof,

~~wherein R2, R3, B and Q are as defined in claim 1;~~ and

R6 is independently

1) H,

2) halogen,

3) $–NO_2$,

4) $–NR^bR^b$,

5) –CN,

6) $-OR^b$,

7) $-SR^b$,

8) $-C(O)R^b$,

9) $(C_1\text{-}C_6)$alkyl,

10) $(C_2\text{-}C_6)$alkenyl,

11) $(C_2\text{-}C_6)$alkynyl,

12) $(C_3\text{-}C_7)$cycloalkyl or

13) $-CF_3$;

~~R^b is as defined in claim 1;~~

L is C(R6), S or N;

n is an integer 1 or 2;

t is an integer from 0 to 3; and

X is a bond or C(R6).

10. (Currently Amended) The use according to ~~any of claims~~claim 1~~, 6, 7, 8 or 9~~, wherein R3 is H or methyl.

11. (Currently Amended) The use according to ~~any of claims~~claim 1~~, 6, 7, 8 or 9~~, wherein D is naphthyl, 4-alkyl-1-naphthyl, benzothiophenyl or indolyl.

12. (Currently Amended) The use according to ~~any of claims~~claim 1~~-11~~, wherein the compound is 4-amino-(*S*)-2-*N*-(4-methyl-1-naphthalenesulfonyl)amino-*N'*-(1,2,3,4-tetrahydro-1-naphthyl)butanamide, 5-amino-(*S*)-2-*N*-(4-methyl-1-naphthalenesulfonyl)amino-*N'*-(1,2,3,4-tetrahydro-1-naphthyl)pentanamide, *N*-benzyl-4-guanidino-(*S*)-2-(*N'*-(4-methyl-1-naphthalenesulfonyl)amino)butanamide, 4-amino-*N*-2-(3-chlorophenyl)ethyl-(*S*)-2-(*N'*-(4-methyl-1-naphthalenesulfonyl)amino)butanamide, 5-*N*-methylamino-(*S*)-2-*N'*-(4-methyl-1-

naphthalenesulfonyl)amino-*N*′′-(1,2,3,4-tetrahydro-1-naphthyl)pentanamide or *N*-benzyl-4-(*N*′-isopropyl)amino-(*S*)-2-(*N*′′-(4-methyl-1-naphthalenesulfonyl)amino)butanamide.

13. (Original) The use according to claim 1 where the disease or condition is depression, anxiety, bipolar disorders, AHDH, angiogenesis, restenosis, new blood vessel sprouting, arteriosclerosis, diabetic angiopathy, diabetic retinopathy, cancerous tumors and tumor metastasis, high introcular pressure or age-related macular degeneration.

14. (Currently Amended) A compound of Formula II



(II)

or a pharmaceutically acceptable salt or ester thereof,

~~wherein R1, R3, A, B and Q are as defined in claim 1~~ wherein

Q is

1) H,

2) aryl,

3) heteroaryl or

4) a group of formula



;

wherein aryl and heteroaryl is unsubstituted or substituted with 1 to 4 substituents selected from R^a;

A is

1) H,

2) $(C_1$-$C_6)$alkyl or

3) $(C_3$-$C_5)$cycloalkyl;

B is independently selected from

1) H,

2) halogen or

3) $(C_1$-$C_6)$alkyl;

or symbols B together may form a double or triple bond between the atoms to which they are attached;

R1 is

1) H,

2) $(C_1$-$C_6)$alkyl or

3) $(C_3$-$C_7)$cycloalkyl;

R3 is

1) H,

2) $(C_1$-$C_6)$alkyl,

3) $(C_2$-$C_6)$alkenyl,

4) $(C_2$-$C_6)$alkynyl or

5) $(C_3$-$C_7)$cycloalkyl;

R^a is independently

1) H,

2) Halogen,

3) $-OR^b$,

4) (C_1-C_6)alkyl or

5) $-CF_3$; and

R2 is independently

1) H,

2) (C_1-C_6)alkyl,

3) (C_2-C_6)alkenyl,

4) (C_2-C_6)alkynyl,

5) (C_3-C_7)cycloalkyl or

6) (C_3-C_7)cycloalkyl(C_1-C_6)alkyl;

or symbols R2 together with the nitrogen to which they are attached form a saturated 5 to 7 membered ring containing 1 to 2 heteroatoms selected from N, O and S;

and when Q is a group of formula



,

then R^4 is ~~as defined in claim 1~~

1) H,

2) (C_1-C_6)alkyl,

3) (C_2-C_6)alkenyl,

4) (C_2-C_6)alkynyl,

5) Cy,

6) Cy-(C_1-C_6)alkyl,

7) Cy-(C_2-C_6)alkenyl or

8) Cy-(C_2-C_6)alkynyl;

wherein alkyl, alkenyl, alkynyl and Cy are each optionally substituted with one to two substituents selected from R^d;

R5 is

1) H,

2) (C_1-C_6)alkyl,

3) (C_2-C_6)alkenyl,

4) (C_2-C_6)alkynyl,

5) aryl,

6) aryl-(C_1-C_6)alkyl,

7) heteroaryl or

8) heteroaryl-(C_1-C_6)alkyl;

wherein aryl and heteroaryl are each optionally substituted with one to four substituents selected from R^d ~~as defined in claim 1~~ where R^d is independently

1) a group selected from R^c,

2) (C_1-C_6)alkyl,

3) (C_2-C_6)alkenyl,

4) (C_2-C_6)alkynyl,

5) aryl,

6) aryl-(C_1-C_6)alkyl,

7) heteroaryl-(C_1-C_6)alkyl,

8) (C_3-C_7)cycloalkyl or

9) heterocyclyl;

wherein alkyl, alkenyl, alkynyl, aryl and heteroaryl are each optionally substituted with one to four substituents independently selected from R^c; or

R4 and R5 together with the atom to which they are attached form a 3 to 8 membered ring containing 0 to 2 heteroatoms selected from N, O and S, wherein the said ring may be substituted with one to three substituents selected from R^d; or the said ring may be fused to aryl or heteroaryl which can be substituted with one to three substituents selected from R^d;

R6 is independently

1) H,

2) halogen,

3) $-NO_2$,

4) $-NR^bR^b$,

5) –CN,

6) $-OR^b$,

7) $-SR^b$,

8) $-C(O)R^b$,

9) $(C_1\text{-}C_6)$alkyl,

10) $(C_2\text{-}C_6)$alkenyl,

11) $(C_2\text{-}C_6)$alkynyl,

12) $(C_3\text{-}C_7)$cycloalkyl or

13) $-CF_3$;

t is an integer from 0 to 3;

n is an integer 1 or 2;

X is a bond or C(R6);

L is C(R6), S or N.

15. (Currently Amended) A compound according to claim 14, which is a compound of Formula IIA,



(IIA)

wherein R2, R3, B, L, X, n and t are as defined in claim 14;

R4 is phenyl or benzyl;

which is unsubstituted or substituted with 1 to 2 substituents selected from R^a ~~as defined in claim 1~~;

R5 is H or $(C_1\text{-}C_6)$alkyl; and

R6 is independently selected from H, halogen or $(C_1\text{-}C_6)$alkyl.

16. (Currently Amended) A compound according to claim 14, which is a compound of Formula IIB,



(IIB)

wherein ~~R3, L, X, R6, Q, n and t are as defined in claim 14; and~~ R2 is independently selected from H, methyl, ethyl, isopropyl, cyclopropyl or cyclohexyl.

17. (Currently Amended) A compound according to ~~any of claims~~claim 14 ~~to 16~~, wherein R3 is H or methyl.

18. (Currently Amended) A compound according to ~~any of claims~~claim 14 ~~to 16~~, wherein L is C(R6), X is a bond or C(R6) and R6 is H.

19. (Currently Amended) A compound according to ~~any of claims~~claim 14 ~~to 17~~, wherein L and X is C(R6) and R6 is independently selected from H, $(C_1\text{-}C_6)$alkyl or halogen.

20. (Currently Amended) A compound according to ~~any of claims~~claim 14 ~~to 16~~, wherein L is N or S and X is a bond.

21. (Currently Amended) A compound of Formula II according to ~~any of claims~~claim 14 ~~to 17 and 19~~, wherein the compound is 4-amino-(*S*)-2-*N*-(4-methyl-1-naphthalenesulfonyl)amino-*N'*-(1,2,3,4-tetrahydro-1-naphthyl)butanamide, 5-amino-(*S*)-2-*N*-(4-methyl-1-naphthalenesulfonyl)amino-*N'*-(1,2,3,4-tetrahydro-1-naphthyl)pentanamide, 4-amino-*N*-2-(3-chlorophenyl)ethyl-(*S*)-2-(*N'*-(4-methyl-1-naphthalenesulfonyl)amino)butanamide, 5-*N*-methylamino-(*S*)-2-*N'*-(4-methyl-1-naphthalenesulfonyl)amino-*N''*-(1,2,3,4-tetrahydro-1-naphthyl)pentanamide or *N*-benzyl-4-(*N'*-isopropyl)amino-(*S*)-2-(*N''*-(4-methyl-1-naphthalenesulfonyl)amino)butanamide.

22. (Currently Amended) A process for preparing a compound as claimed in ~~any of~~ ~~claims~~claim 14 ~~to 21~~, comprising reacting an amidated amino acid of Formula III,



(III)

wherein ~~R1, A, B, Q and n are as defined in any one of claims 14 to 21;~~ R2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or a protecting group; R3 is H, alkyl, cycloalkyl or a protecting group, with a sulfonyl acid derivative of Formula IV,



(IV)

wherein ~~R6, L, X, n and t are as defined in any one of the claims 14 to 21;~~ W is OH or a halogen, especially Cl or Br, and where the compounds of Formula III and IV being optionally protected.

23. (Original) A pharmaceutical composition compromising a compound of Formula II according to claim 14 as an active ingredient together with a pharmaceutically acceptable diluent, carrier and/or excipient.

24. (Original) The use of a compound of Formula II according to claim 14 for the imaging of healthy or diseased tissues and/or organs, such as brain, blood vessels or tumors, possessing SSTR1 and/or SSTR4 receptors.

25. (Original) The use of a compound of Formula II according to claim 14 for the preparation of a medicament for treating a disease or condition in mammals where an interaction with somatostatin receptor subtypes 1 and/or 4 is indicated to be useful.

26. (Original) The use according to claim 25, where the compound is an agonist.

27. (Original) The use according to claim 25, where the compound is an antagonist.

28. (Original) The use according to claim 25, where the compound is SSTR1 selective.

29. (Original) The use according to claim 25, where the compound is SSTR4 selective.

30. (Original) The use according to claim 25, where the disease or condition is depression, anxiety, bipolar disorders, AHDH, angiogenesis, restenosis, new blood vessel sprouting, arteriosclerosis, diabetic angiopathy, diabetic retinopathy, cancerous tumors and tumor metastasis, high introcular pressure or age-related macular degeneration.